Median progression-free survival measured from randomization was 4.1 months on the ALIMTA arm as compared to 2.8 months on the placebo arm with a hazard ratio of 0.62. Stated another way, the study showed that patients on the ALIMTA continuation maintenance arm had a 38 percent improvement of survival without disease worsening, compared to the placebo arm.The most severe adverse reactions (grades 3-4) with ALIMTA as a single agent versus placebo, respectively, for these patients in the maintenance setting were anemia (4.8% vs 0.6%); neutropenia (3.9% vs 0%); fatigue (4.5% vs 0.6%).
ALIMTA® Extends Survival In Continuation Maintenance Setting For Specific Lung Cancer Patients
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.